Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Dabrafenib and trametinib cost?
Tenofovir generic patent?
Novartis patent term dabrafenib?
When is tenofovir alafenamide patent expiring?
Dabrafenib patent expiration date novartis gsk composition matter?

Uptravi biopharmaceutical company?

See the DrugPatentWatch profile for Uptravi

Uptravi is the brand name for selexipag, a drug for pulmonary arterial hypertension.

- Originally developed by Actelion Pharmaceuticals Ltd. (a Swiss biopharma).
- Actelion was acquired by Johnson & Johnson in 2017, and Uptravi is now marketed by Janssen Pharmaceuticals (the J&J subsidiary).
- In Japan, the rights are held by Nippon Shinyaku Co., Ltd., under license for that market.

So, the core biopharma company behind Uptravi is Actelion (now part of Janssen, Johnson & Johnson).



Other Questions About Uptravi :

evaluate the pharmaceutical company uptravi on brand name / misspellings Uptravi merck pharmaceutical company overview? Evaluate the pharmaceutical company uptravi on brand name misspellings? Uptravi patent expiration? Uptravi patent expiration date? Uptravi generic availability or launch or entry 2025 or 2026? Uptravi brand name misspellings?